The results of a phase 2 trial of MSD’s ROR1 inhibitor zilovertamab vedotin (zilo-V) back up the company's decision to push the antibody-drug conjugate (ADC) into a phase 3 programme.

Jon Willis has been selected as chief operating officer for ZILO, as part of the executive leadership team. Willis joins the position from HSBC Securities Services, where he remained for over five ...

State Street participated in ZILO’s Series A fundraising round in January 2024, a decision driven by State Street’s focus on addressing the need for modern digital solutions to improve cost ...

Fintech firm ZILO has launched its software-as-a-service technology platform for global transfer agency services. The solution uses a single platform across jurisdictions, providing users with ...

UK-based fintech ZILO has supported State Street in the launch of its transfer agency offering in the UK and the onboarding of River Global. This displays ZILO's record of transforming transfer ...